Helicobacter pylori-associated immune thrombocytopenia: Clinical features and pathogenic mechanisms

Figure 1 Changes in platelet count and in anti-GPIIb/IIIa antibody-producing circulating B cells before and 3 mo after an Helicobacter pylori eradication regimen in Helicobacter pylori-positive immune thrombocytopenia patients with no additional disease, or with systemic lupus erythematosus or liver cirrhosis. Changes in absolute values were compared by paired t test. ^aP < 0.05. A dotted line indicates the cut-off for circulating anti-GPIIb/IIIa antibody-producing B cells, which was 2/10⁵ peripheral blood mononuclear cells (PBMCs). ITP: Immune thrombocytopenia; SLE: Systemic lupus erythematosus.